197 related articles for article (PubMed ID: 19262468)
1. Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design.
Kohro T; Yamazaki T
Hypertens Res; 2009 Feb; 32(2):109-14. PubMed ID: 19262468
[TBL] [Abstract][Full Text] [Related]
2. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
3. An orwellian discourse on the meaning and measurement of noninferiority.
Diamond GA; Kaul S
Am J Cardiol; 2007 Jan; 99(2):284-7. PubMed ID: 17223435
[TBL] [Abstract][Full Text] [Related]
4. [Clinical trials: principles of the method].
Aboulker JP
Rev Prat; 2000 Apr; 50(8):829-32. PubMed ID: 10874858
[TBL] [Abstract][Full Text] [Related]
5. Randomized clinical trials on surrogate end points: are they useful for evaluating cardiovascular and renal disease protection in hypertension? The case for yes.
Morganti A
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S141-4. PubMed ID: 16565239
[TBL] [Abstract][Full Text] [Related]
6. A review of cohort study design for cardiovascular nursing research.
Hood MN
J Cardiovasc Nurs; 2009; 24(6):E1-9. PubMed ID: 19858946
[TBL] [Abstract][Full Text] [Related]
7. Statistical significance versus clinical relevance in cardiovascular medicine.
Willenheimer R
Prog Cardiovasc Dis; 2001; 44(3):155-67. PubMed ID: 11727275
[TBL] [Abstract][Full Text] [Related]
8. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
9. [Instructions and methods for clinical trials of medicinal products for the treatment of chronic systolic heart failure].
Wink K
Arzneimittelforschung; 2008; 58(9):475-9. PubMed ID: 18972879
[TBL] [Abstract][Full Text] [Related]
10. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
Le Tourneau C; Michiels S; Gan HK; Siu LL
J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
[TBL] [Abstract][Full Text] [Related]
11. From randomized controlled trials to observational studies.
Silverman SL
Am J Med; 2009 Feb; 122(2):114-20. PubMed ID: 19185083
[TBL] [Abstract][Full Text] [Related]
12. Review of randomised clinical trials of cardiovascular generic versus brand name drugs.
Cardiovasc J Afr; 2009; 20(2):143. PubMed ID: 19421653
[No Abstract] [Full Text] [Related]
13. Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity.
Dyck PJ; Norell JE; Tritschler H; Schuette K; Samigullin R; Ziegler D; Bastyr EJ; Litchy WJ; O'Brien PC
Diabetes Care; 2007 Oct; 30(10):2619-25. PubMed ID: 17513707
[TBL] [Abstract][Full Text] [Related]
14. [From clinical trials to routine treatment. General aspects of clinical trials in cardiovascular diseases].
Reikvam A
Tidsskr Nor Laegeforen; 1994 Feb; 114(4):455-8. PubMed ID: 8009484
[TBL] [Abstract][Full Text] [Related]
15. Advancing the science of aspirin in primary prevention of vascular events.
Cardiovasc J Afr; 2007; 18(5):347-8. PubMed ID: 17985039
[No Abstract] [Full Text] [Related]
16. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point.
Hansson L; Hedner T; Dahlöf B
Blood Press; 1992 Aug; 1(2):113-9. PubMed ID: 1366259
[TBL] [Abstract][Full Text] [Related]
17. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
Becker MC; Wang TH; Wisniewski L; Wolski K; Libby P; Lüscher TF; Borer JS; Mascette AM; Husni ME; Solomon DH; Graham DY; Yeomans ND; Krum H; Ruschitzka F; Lincoff AM; Nissen SE;
Am Heart J; 2009 Apr; 157(4):606-12. PubMed ID: 19332185
[TBL] [Abstract][Full Text] [Related]
18. Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?
Cohn J; Cleland JG; Lubsen J; Borer JS; Steg PG; Perelman M; Zannad F
J Card Fail; 2009 Apr; 15(3):199-205. PubMed ID: 19327621
[TBL] [Abstract][Full Text] [Related]
19. Informed choice of composite end points in cardiovascular trials.
Gómez G; Gómez-Mateu M; Dafni U
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):170-8. PubMed ID: 24425702
[TBL] [Abstract][Full Text] [Related]
20. Topics in clinical research. III. The importance of randomized, double-blind procedures in clinical trials.
Bell DS
Clin Ther; 1989; 11(5):565-7. PubMed ID: 2805022
[No Abstract] [Full Text] [Related]
[Next] [New Search]
